NanoMedSyn is open to collaborations with biotechnology companies, academic groups, and pharmaceutical partners. Our flexible and modular AMFA glycoligands platform offers broad potential for rapidly developing differentiated delivery and degradation solutions across diverse disease areas. We offer co-development, partnerships, and licensing around AMFA-enabled conjugation and delivery technologies, while pursuing selected internal programs to de-risk high impact indications.
Intellectual Property
NanoMedSyn’s AMFA chemistry and applications are protected by a strong patent estate covering composition, receptor engagement, and therapeutic uses, thereby ensuring secure and defensible collaborations across global markets.